Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 4/20 | 0.39 |
| ▸ | PPARD | Q03181 | 4/20 | 0.39 |
| ▸ | BRD4 | O60885 | 2/20 | 0.36 |
| ▸ | BRDT | Q58F21 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.35 |
| ▸ | ELANE | P08246 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.35 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.35 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.35 |
| ▸ | PDGFRB | P09619 | 1/20 | 0.35 |
| ▸ | FFAR4 | Q5NUL3 | 1/20 | 0.35 |
| ▸ | MET | P08581 | 3/20 | 0.34 |
| ▸ | KDR | P35968 | 1/20 | 0.34 |
| ▸ | PARP15 | Q460N3 | 1/20 | 0.34 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.34 |
| ▸ | PRKAB2 | O43741 | 2/20 | 0.34 |
| ▸ | PRKAG1 | P54619 | 2/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2433373 | 0.85 | TDP1 (0.38) | BRD4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1136059 | 0.80 | MET (0.40) | BRD4PDE4APDE4BPDE4CPDE4D | |
| SCHEMBL1135964 | 0.78 | MAOB (0.39) | BRDTPDE4DPDGFRBMETKDR | |
| SCHEMBL2523334 | 0.77 | PDE4A (0.41) | BRD4MEN1KMT2APDE4APDE4B | |
| SCHEMBL1136191 | 0.77 | MET (0.38) | FFAR1PPARDBRD4FFAR4MET | |
| SCHEMBL2430551 | 0.76 | BRDT (0.39) | BRDTPDE4B | |
| SCHEMBL2433050 | 0.75 | TDP1 (0.37) | BRD4ELANEPDE4APDE4BPDE4C | |
| SCHEMBL2434890 | 0.74 | ADORA3 (0.38) | BRDTMEN1KMT2APDE4B | |
| SCHEMBL1136159 | 0.74 | MAOB (0.36) | FFAR1PPARDBRDTPDGFRBMET | |
| SCHEMBL2433628 | 0.73 | PDE4B (0.38) | MEN1KMT2APDE4BPRKAB2PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2364706-B1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2015-07-29 | — | — | EP | disclosed |
| EP-2364706-B1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMA CO LTD (JP) | 2015-07-29 | — | — | EP | disclosed |
| US-20130217678-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20130217678-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20130217678-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2013-08-22 | — | — | US | disclosed |
| US-20110251180-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
| US-20110251180-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
| US-20110251180-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2011-10-13 | — | — | US | disclosed |
| EP-2364706-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | Otsuka Pharmaceutical Co., Ltd. (JP) | 2011-09-14 | — | — | EP | disclosed |
| EP-2364706-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | Otsuka Pharmaceutical Co., Ltd. (JP) | 2011-09-14 | — | — | EP | disclosed |
| WO-2010064701-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | 大塚製薬株式会社 (JP) | 2010-06-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110251180-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | PARK7, SNCA, LRRK2 | FFAR1 1826/4885PPARD 1901/4885BRD4 915/4885 |
| US-20130217678-A1 | PHARMACEUTICAL AGENT COMPRISING QUINOLONE COMPOUND | PARK7, SNCA, LRRK2 | FFAR1 1826/4885PPARD 1901/4885BRD4 915/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.